Perspectives on optimizing trial design and endpoints in peripheral arterial disease: a case for imaging-based
Sanjay Rajagopalan1, Georgeta Mihai
1Division of Cardiovascular Medicine, Department of Internal Medicine, The Ohio State University, 473 West 12 Avenue, Columbus, OH 43210, USA. Sanjay.rajagopalan@osumc.edu
Abstract:
Surrogate endpoints are important for validation of mechanism, early proof of concept, and the rational design of clinical trials for regulatory approval of drugs. The recent failure of several drugs in peripheral arterial disease (PAD) and in atherosclerosis highlights the importance of understanding drug effect and is a clarion call for better endpoints. This review focuses on aspects relating to the current state of surrogate endpoints in PAD and reviews emerging endpoints using imaging approaches that may have the potential of improving study design in PAD.
Related Concept Videos
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease IV: Nursing Management
Peripheral Artery Disease I: Introduction
Peripheral Artery Disease V: Postoperative Nursing Management


